Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

  • Thomas Dörner1Email author,

    Affiliated with

    • Joerg Kaufmann1,

      Affiliated with

      • William A Wegener2,

        Affiliated with

        • Nick Teoh2,

          Affiliated with

          • David M Goldenberg2, 3 and

            Affiliated with

            • Gerd R Burmester1

              Affiliated with

              Arthritis Research & Therapy200810:406

              DOI: 10.1186/ar2499

              Published: 9 September 2008


              Following publication of our article [1] we noticed an error in the stated dose of methotrexate within the section 'Results', in the paragraph 'Demographics and patient characteristics at study entry'.

              In this paragraph, it is stated that two patients were receiving 20 mg/day methotrexate. This should read 20 mg/week methotrexate.

              The paragraph should therefore read as follows:

              A total of 14 Caucasian patients (13 females and 1 male; 23 to 53 years old, median age 40 years) were enrolled. At study entry, the patients had been initially diagnosed with SLE 1 to 19 years (median 10 years) earlier and were receiving corticosteroids (n = 13, 1 to 12 mg/day prednisolone) plus immunosuppressives (n = 11, including 50 to 200 mg/day azathioprine, n = 9; 20 mg/week methotrexate, n = 2; 2 g/day mycophenalate mofetil, n = 1), and antimalarials (n = 6, 200 to 600 mg/day hydroxychloroquine). All patients had positive ANA at study entry (titers of 80:1 to 5,120:1), and 5 patients (36%) had positive anti-dsDNA antibody levels (> 10 U/ml). Ten patients (71%) had ESR values that were elevated (> 15 mm/h) and 4 patients (29%) had raised CRP levels (> 0.5 mg/dl), while only 3 patients (21%) had C3 levels that were borderline low or decreased (< 90 mg/dl), and no patient had positive direct Coombs' or serum haptoglobulin levels elevated above borderline.

              Authors’ Affiliations

              Department of Medicine/Rheumatology and Clinical Immunology, Charite Hospital
              Immunomedics, Inc.
              Center for Molecular Medicine and Immunology


              1. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Research & Therapy 2006, 8:R74.View Article


              © BioMed Central Ltd 2008